生物股份(600201.SH):子公司獲得獸用生物製品臨牀試驗批件
格隆匯7月25日丨生物股份(600201.SH)公佈,全資子公司金宇保靈生物藥品有限公司(簡稱“金宇保靈”)收到了農業農村部頒發的貓傳染性腹膜炎mRNA疫苗臨牀試驗批件。貓傳染性腹膜炎是一種由貓傳染性腹膜炎病毒(FelineInfectiousPeritonitisVirus,FIPV)引起的致死性烈性傳染病,致死率可高達100%,嚴重威脅到貓的生命健康,目前尚未有商品化疫苗可以使用。金宇保靈聯合相關單位共同開發的貓傳染性腹膜炎mRNA疫苗,在抗原設計階段科研人員深入研究FIPV病毒的感染與免疫機制,結合AI算法與結構生物學對抗原進行了細緻的篩選及優化,通過高通量的本動物免疫攻毒實驗得到了有效保護的核心靶點設計。截至目前,該產品累計研發投入金額約620萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.